Publications

Phase Iii Study of Neoadjuvant Pembrolizumab or Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple-Negative Breast Cancer (Tnbc): Keynote-522 Korean Subgroup Analysis

AuthID
P-00Z-QT2

Author(s)

Park, YH

Im, SA

Ahn, JH

Kim, MH

Cortés, J

Dent, RA

Pusztai, L

McArthur, HL

Kummel, S

Denkert, C

O'Shaughnessy, J

Mouret Reynier, MA

Ferreira, MIR

Cortes, MG

Boileau, JF

Hui, R

Zhu, Y

Pan, W

Karantza, VV

Schmid, P

Document Type

Abstract

Year published

2023

Published

in ANNALS OF ONCOLOGY, ISSN: 0923-7534

Volume: 34, Pages: S1467-S1468 (2)

Conference

Annual Meeting of the European-Society-For-Medical-Oncology (Esmo), Date: DEC 01-03, 2023, Location: SINGAPORE

Indexing

Wos^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.annonc.2023.10.132

Wos: WOS:001122475400003

Source Identifiers

ISSN: 0923-7534

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Phase Iii Study of Neoadjuvant Pembrolizumab or Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple-Negative Breast Cancer (Tnbc): Keynote-522 Korean Subgroup Analysis

Useful Links

Get Help

Federated Authentication (Click on the image)

Phase Iii Study of Neoadjuvant Pembrolizumab or Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple-Negative Breast Cancer (Tnbc): Keynote-522 Korean Subgroup Analysis

Useful Links

Get Help